1. Scrip
  2. >>Focus On Asia
  3. >>India

Eisai-Mylan Tango for Second Halaven Brand In India But Eyes On Pricing, Generics

 
• By Anju Ghangurde

Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.

Holding_Arrow
Mylan To Market Second Brand Of Eisai's Halaven In India • Source: Shutterstock

Eisai Co. Ltd., has firmed up a licensing deal with Mylan NV for a second brand of Halaven (eribulin mesylate), as the Japanese company seeks to expand availability and access to the anticancer on the Indian market amid the recent arrival of a cut-price rival.

The licensing agreement will see Mylan India promote and distribute the second brand, Teceris, in the country, with eribulin being supplied by Eisai India

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia